GL1X · GenesisL1 explorer

MolNFT v1 · #125883 · protein

Human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor

5LMB · Tyrosine-protein kinase syk: “Human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor”. X-ray diffraction, 1 ligand (6ZF), 5 pockets (best druggability 0.68). MolNFT v1 #125883 on GenesisL1: 3D…

PDB
5LMB
Type
protein
Length
527 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tyrosine-protein kinase syk
EC
2.7.10.2
UniProt
P43405
Ligands
6ZF
Pockets
5 · best druggability 0.68

Structure

x-ray diffraction · 2 distinct chains · 40% helix, 24% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein kinase syk (EC 2.7.10.2)protein26540% helix, 23% strandP43405
BTyrosine-protein kinase syk (EC 2.7.10.2)protein26239% helix, 25% strandP43405

Ligands and binding sites

  • 6ZF · 7-[6-(dimethylamino)pyridin-3-yl]-~{N}-[[(3~{S})-piperidin-3-yl]methyl]pyrido[3,4-b]pyrazin-5-amine · ligand · 2 copies · chains A, B
  • GOL · Glycerol · additive · 7 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15660.680.78636ZF, GOL
22830.620.80366ZF
32290.540.7733GOL
4980.340.7319empty
5600.300.7516empty

Interfaces

1 interface between chains.

  • A–B · 580 Ų buried · 9 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 modified (phosphorylation).

Compared structures

  • 5LMB · Human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.